Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2023-08-10 |
2023-06 |
-0.09 |
N/A |
N/A |
N/A |
2023-05-15 |
2023-03 |
-0.32 |
N/A |
N/A |
N/A |
2023-03-30 |
2022-12 |
-0.31 |
N/A |
N/A |
N/A |
2022-11-14 |
2022-09 |
-0.39 |
N/A |
N/A |
N/A |
2022-08-11 |
2022-06 |
-0.59 |
N/A |
N/A |
N/A |
2022-05-16 |
2022-03 |
-0.57 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-06-01 |
Oppenheimer |
Downgrade |
Outperform |
Perform |
2023-05-16 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-03-31 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2022-08-16 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-07-19 |
Oppenheimer |
Upgrade |
|
Outperform |
2021-09-24 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-06-06 |
BIERMAN JAMES L |
Director |
40.10K |
Conversion of Exercise of derivative security |
2023-06-06 |
GAY JOHN M. |
Chief Financial Officer |
46.83K |
Conversion of Exercise of derivative security |
2023-06-06 |
GEER W KENT |
Director |
37.68K |
Conversion of Exercise of derivative security |
2023-06-06 |
KEEGAN ROBERT J |
Director |
42.40K |
Conversion of Exercise of derivative security |
2019-07-01 |
MALIN LIFE SCIENCES HOLDINGS, LTD. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2019-05-28 |
MARTIN G KELLY |
Chief Executive Officer |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-03-30 |
Armistice Capital, LLC |
2.25M |
1.26M |
8.02% |
2023-03-30 |
Vanguard Group, Inc. (The) |
807.99K |
453.85K |
2.88% |
2023-03-30 |
Blackrock Inc. |
302.31K |
169.81K |
1.08% |
2023-03-30 |
B. Riley Wealth Advisors, Inc. |
187.00K |
105.04K |
0.67% |
2023-03-30 |
Geode Capital Management, LLC |
150.45K |
84.51K |
0.54% |
2023-03-30 |
Renaissance Technologies, LLC |
85.37K |
47.95K |
0.30% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Vanguard Total Stock Market Index Fund |
545.36K |
306.33K |
1.95% |
2022-12-30 |
Vanguard Extended Market Index Fund |
210.18K |
118.06K |
0.75% |
2023-02-27 |
Fidelity Extended Market Index Fund |
81.81K |
45.95K |
0.29% |
2023-02-27 |
iShares Micro Cap ETF |
41.29K |
23.19K |
0.15% |
2023-02-27 |
Fidelity Series Total Market Index Fund |
27.73K |
15.58K |
0.10% |
2023-02-27 |
Fidelity Total Market Index Fund |
20.46K |
11.49K |
0.07% |
Split |
Date |
1 : 10 |
2021-05-26 |
1 : 10 |
2021-05-25 |